Elicera Therapeutics’ co-founders receive additional grants totalling 7,65 MSEK from the Swedish Cancer Society to support CAR T research
Gothenburg, November 16, 2022 - Elicera Therapeutics AB (publ) (“Elicera”), a clinical stage cell and gene therapy company developing next-generation therapies based on oncolytic viruses and CAR T-cells armed with the company’s proprietary and commercially available platform iTANK, today announced that co-founders Professor Magnus Essand and Associate Professor Di Yu have received a total of 7,65 MSEK in funding from the Swedish Cancer Society to support their CAR T research programmes in progress at Uppsala University.Elicera will not be a direct recipient of the funding. The outcomes of